Chronic Lymphocytic Leukemia

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

Minimal residual disease status was associated with progression-free survival in chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss matching-adjusted indirect comparisons of BTK inhibitors in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Stephen Opat, MBBS, discusses the accessibility of sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Stephen Opat, MBBS, discusses sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab elicited favorable PFS outcomes in previously untreated chronic lymphocytic leukemia.

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.

Moritz Fürstenau, MD, discusses the rationale for launching the phase 3 GAIA/CLL13 in previously untreated, fit patients with chronic lymphocytic leukemia.

Pembrolizumab plus ibrutinib or idelalisib produced responses in patients with Richter transformation of chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

Moritz Fürstenau, MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.

Tycel Phillips, MD, discusses the evolution of treatment strategies for patients with either chronic lymphocytic leukemia or mantle cell lymphoma.

Moritz Fürstenau MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.